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ABSTRACT
There are marked differences in methods used for undertaking economic evaluations across low-income, middle-income,
and high-income countries. We outline the most apparent dissimilarities and reﬂect on their underlying reasons. We ran-
domly sampled 50 studies from each of three country income groups from a comprehensive database of 2844 economic
evaluations published between January 2012 and May 2014. Data were extracted on ten methodological areas: (i) availa-
bility of guidelines; (ii) research questions; (iii) perspective; (iv) cost data collection methods; (v) cost data analysis; (vi)
outcome measures; (vii) modelling techniques; (viii) cost-effectiveness thresholds; (ix) uncertainty analysis; and (x)
applicability. Comparisons were made across income groups and odds ratios calculated. Contextual heterogeneity rightly
drives some of the differences identiﬁed. Other differences appear less warranted and may be attributed to variation in
government health sector capacity, in health economics research capacity and in expectations of funders, journals and peer
reviewers. By highlighting these differences, we seek to start a debate about the underlying reasons why they have occurred
and to what extent the differences are conducive for methodological advancements. We suggest a number of speciﬁc areas
in which researchers working in countries of differing environments could learn from one another. © 2016 The Authors.
Health Economics published by John Wiley & Sons Ltd.
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1. INTRODUCTION
Economic evaluation (EE) is deﬁned as a ‘comparative analysis of alternative courses of action in terms of both
their costs and their consequences’ (Drummond et al., 2005). EEs aim to identify how to employ scarce
resources most efﬁciently to improve health, thereby achieving ‘value for money’. The number of EE studies
has increased substantially over the past three decades, both in high-income (Neumann et al., 2009, Greenberg
et al., 2010) and in low-income and middle-income settings (Suhrcke et al., 2012). In a bibliometric analysis
published in this special issue, Pitt et al. (2016) found that more than 100 EEs were published every month
during 2012–2014.
The quality of EEs has been assessed in several reviews, which have generally concluded that a relatively
large proportion of studies do not adhere to standard guidance (Jefferson et al., 2002, Gerard et al., 1999,
Neumann et al., 2000). Consequently, several checklists that stipulate requirements of what a high-quality
study should contain and report have been developed (Husereau et al., 2013, Drummond and Jefferson,
1996). Reviews of EEs often use these checklists for quality assessments (Fang et al., 2011, Grifﬁths and
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Miners, 2009). However, to date no review has directly compared the methods used for EE across country in-
come groups.
In this paper, we identify some of the most important methodological differences between EEs in low-
income, middle-income, and high-income countries, reﬂect on the reasons for the dissimilarities and discuss
implications for research standards.
2. METHODS
2.1. Identiﬁcation of areas of methodological difference
We identiﬁed ten methodological areas in which we expected to ﬁnd marked differences across settings. These
were partly based on the Consolidated Health Economic Evaluation Reporting Standards checklist (Husereau
et al., 2013) and from our experience working in low-income, middle-income and high-income countries.
The ten areas are as follows: (i) availability of guidelines; (ii) research questions; (iii) perspective; (iv) cost data
collection methods; (v) cost data analysis; (vi) outcome measures; (vii) modelling techniques; (viii) cost-
effectiveness thresholds; (ix) uncertainty analysis; and (x) applicability. In Section 3, we describe each
methodological topic in turn. Our perceptions of the underlying reasons for the differences are given in the
discussion.
2.2. Cross-sectional analysis of methodological differences across country income groups
To quantify the degree of methodological variation between country income groups, we conducted a cross-
sectional analysis of a representative sample of recently published EEs. We randomly selected a stratiﬁed sam-
ple of 150 studies from a comprehensive database of 2844 EEs published between 1 January 2012 and 3 May
2014 (Pitt et al., 2016). Pitt and colleagues constructed this database by systematically searching 14 literature
databases, screening more than 15 000 unique records and retaining only primary research articles, which either
produced a summary measure of efﬁciency (such as an incremental cost-effectiveness ratio, incremental net
beneﬁt, probability of cost-effectiveness given a threshold or a cost-effectiveness plane or acceptability curve)
or demonstrated strict dominance. Articles described as cost-effectiveness or cost-beneﬁt analyses, but not
meeting these inclusion criteria, were excluded.
Fifty articles were sampled from each of three country income groups: low-income and lower-middle-income
countries (LLMICs, gross national income (GNI) per capita<US$ 4083), upper-middle-income countries
(UMICs, US$ 4086< x<US$ 12 615) and high-income countries (HICs, GNI per capita>US$ 12 616)
(World Bank, 2014). We chose to combine low-income and lower-middle income countries into one group
because the overall number of studies in each group were small and we believe that the capacity for EE
research in these countries is comparably low. Multi-country studies spanning more than one of the three
income groups were excluded, while multi-country studies that examined countries within only one of the
three income groups were included. Sampling was performed using Excel’s random number generator to
assign a random value between 0 and 1 to all articles, and then selecting the 50 articles within each group with
the highest values. We extracted data from the full texts of the 150 articles using a standardised data extraction
tool reﬂecting the ten methodological areas. We then compared ﬁndings in these methodological areas across
income groups and performed a logistic regression to estimate the odds of income group being a predictor of
the chosen method. Full references of the 150 selected studies are included in the web annex.
2.3. Other sources of evidence
For each of the ten methodological areas, we also examined other relevant evidence. In particular, we identiﬁed
country-speciﬁc EE guidelines on the website of the International Society for Pharmacoeconomics and Out-
comes Research (International Society for Pharmacoeconomics & Outcomes Research, 2015).
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3. RESULTS
3.1. Published guidelines
In HICs, EEs have frequently been conducted as part of health technology assessments (HTAs). This is ‘a form
of policy research that examines short-term and long-term consequences of a healthcare technology, including
evidence of safety, efﬁcacy, patient-reported outcomes, cost and cost-effectiveness’ (International Society for
Pharmacoeconomics & Outcomes Research, 2003). HTA originated in the USA in the 1960s, but the approach
has especially been embraced in Western Europe (Neumann, 2009). During the 1980s, government HTA of-
ﬁces were established in several European countries, and these gradually began to publish HTA guidelines,
which included speciﬁc guidance on the conduct and reporting of EEs (O’Donnell et al., 2009, Philips et al.,
2004). Importantly, HTA with an EE component has become compulsory in several countries when assessing
whether a new pharmaceutical product should be reimbursed by publicly funded healthcare systems. The
requirement to demonstrate that new products are cost-effective as well as of good quality, effective and safe
has been described as the ‘fourth hurdle’ (Rawlins, 2012).
As of mid 2015, 50% of HICs, 20% of UMICs and 1% of LLMIC had ofﬁcial EE guidelines (Table I).
While an application of these guidelines was only a recommendation in ten countries, it was a requirement
for reimbursement or inclusion in publicly provided services in the remaining 30. Australia was the ﬁrst HIC
to publish guidelines in 1992, joined most recently by Italy, Croatia, Slovak Republic and Finland in 2011.
The median year for the ﬁrst edition of guidelines in HICs was 2003. In 2003, Cuba was the ﬁrst UMIC to pub-
lish HTA guidelines, and between 2008 and 2014, an additional eight UMICs also did this: Mexico (2008),
Thailand (2008), Brazil (2009), South Africa (2010), China (2011), Malaysia (2012), Hungary (2013) and
Colombia (2014). Egypt is the only LLMIC with ofﬁcial guidelines, issued in 2013.
Instead of national guidelines, researchers working in LLMICs have tended to use guidance published by
international organisations, in particular, theWorld Health Organization (WHO). These guidelines have often been
produced for disease-speciﬁc programmes, such as for vector control and immunisation (Phillips et al., 1993,
Walker et al., 2010). However, several of them have focused more on estimation of intervention costs than on
effect measurement (Kumaranayake et al., 2000, World Health Organization, 1988). In 2003, the WHO published
guidelines for ‘Generalised Cost-effectiveness Analysis’ (Edejer et al., 2003), but this method has not been widely
applied outside this organisation. During 2013–2014, the Bill andMelinda Gates Foundation funded development
of a ‘reference case’ with the objective of increasing the consistency of EE methodology for studies undertaken in
low-income and middle-income countries (NICE International, 2014, Santatiwongchai et al., 2015). The reference
case is founded on 11 key principles to guide the planning, conduct and reporting of EEs. Some of these principles
are quite speciﬁc compared with the Consolidated Health Economic Evaluation Reporting Standards checklist,
which only lists items that should be included when reporting EEs. For example, the Bill and Melinda Gates
Foundation reference case recommends using an outcome measure that is generalisable across disease states
and to include a budget impact analysis as well as an equity analysis (NICE International, 2014).
Table I. Availability of ofﬁcial economic evaluation guidelines
Country income group
Number of
countries
Number of
countries with
methodological
recommendations
Number of
countries with
methodological
requirements for
reimbursement
Number of
countries with
any economic
evaluation
guidelines
Median year
of ﬁrst edition
Low-income and lower-middle income 84 0 (0%) 1 (1%) 1 (1%) 2013
Upper-middle income 51 3 (6%) 6 (12%) 9 (18%) 2011
High-income 60a 7 (12%) 23 (38%) 30 (50%) 2003
Total 195 10 (5%) 30 (15%) 40 (21%) 2006
Source: ISPOR website (International Society for Pharmacoeconomics & Outcomes Research, 2015).
aScotland and Taiwan are counted as independent countries as they have their own guidelines.
Income groups reﬂect World Bank classiﬁcations (2014).
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3.2. Research questions
In our cross-sectional analysis, we found that the majority (56%) of LLMIC studies examined infectious diseases,
as did a large proportion (39%) of UMIC studies, compared with just 14% of HIC studies (Tables S1–S3 in
Supporting Information). Chronic conditions, deﬁned as diseases not passed from person to person and of long
duration, were studied in 22% of LLMIC studies, 62% of UMIC studies and 80% of HIC studies. Other health
problems, including malnutrition, obstetric emergencies, iodine deﬁciency and fractures, were studied in 22% of
LLMIC studies and in just 2% and 6% of UMIC and HIC studies, respectively. The logistic regression showed that
the odds of studying a chronic disease were 3.83 greater for each increase in income group (Table III). These trends
largely mirror the 2011 global burden of disease estimates, although in all income groups, infectious diseases are
studied in a substantially higher proportion of studies than their share of the disease burden. Infectious diseases
accounted for 33% of the disease burden in LLMICs, 11% in UMICs and 4% in HICs. Chronic conditions, by
our deﬁnition, constituted 41% of the disease burden in LLMICs, 71% in UMICs and 84% in HICs (World Health
Organization, 2014).
The types of interventions evaluated varied considerably by income group. While new drugs were evaluated
in 36% and 24% of the UMIC and HIC papers, respectively, none of the 50 studies set in LLMICs evaluated a
new drug (Table II). Instead, 26% of LLMIC papers assessed an increased use of a mature drug already prevail-
ing in the essential drug list of the country, and 42% evaluated the introduction of new services. New services
in LLMICs were often relatively complex interventions, such as school support for orphan girls to prevent
human immunodeﬁciency virus infection (Miller et al., 2013), mobile phone text messages to health workers
with reminders about malaria treatment procedures (Zurovac et al., 2012) and increased leprosy case detection
(Ezenduka et al., 2012).
3.3. Perspective of analysis
The perspective taken in an EE determines whose costs should be taken into account. There are generally two
main perspectives to consider, the health sector (i.e. provider or third party payer) and society. When using a
health sector perspective, costs borne by patients and their families or by other sectors are excluded. In the
societal perspective, all costs are included irrespective of who pays. Time costs, also referred to as productivity
costs, should also be included in the societal perspective.
The government health sector perspective is required in the primary analysis of 55% of the EE guidelines
from HICs and UMICs (International Society for Pharmacoeconomics & Outcomes Research, 2015). The
US guidelines recommend a payer perspective in primary analysis and societal in secondary analysis, reﬂecting
the country’s insurance-based health care ﬁnancing (Academy of Managed Care Pharmacy, 2012). In contrast,
the societal viewpoint is consistently recommended as the preferred perspective in guidelines used by LLMIC
researchers (Edejer, 2003, Walker et al., 2010). However, the Egyptian guidelines only require a government
health sector perspective (Elsisi et al., 2013).
Table II. Types of interventions evaluated in sample of 150 articles
Type of intervention LLMIC (%) UMIC (%) HIC (%)
New service 42 8 18
Increased use of old drug 26 14 14
New vaccine 14 16 6
Surgery 10 6 12
Nutrition 4 4 0
Screening 2 14 16
Diagnostics 2 2 10
New drug 0 36 24
LLMIC, low-income and lower-middle income countries; UMIC, upper-middle-income countries; HIC, high-income
countries.
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The guideline recommendations were to some extent reﬂected in the ﬁndings of our cross-sectional analysis.
A government health sector perspective was taken in 70% of the HIC studies, 66% of the UMICs and 60% of
the LLMICs. A societal perspective was taken in 18%, 20% and 36% of the studies from HICs, UMICs and
LLMICs, respectively. A payer’s perspective was used in 12% of both HIC and UMIC studies and in none
of the LLMIC studies. The patient’s perspective was used in 2% of the UMIC studies and 3% of the LLMIC
studies, but in none of the HIC studies. The differences between income groups in the proportion of studies
employing a government health sector perspective were not, however, statistically signiﬁcant (p=0.295,
Table III).
3.4. Cost data collection methods
Costing methods should follow from the aim of the analysis and the availability of data (Mogyorosy and Smith,
2005). At one end of the spectrum, the ingredient approach, or micro-costing, entails direct measurement of re-
sources and their associated unit costs. If relevant for the analysis, patient-speciﬁc data collection is preferable
because it allows for more detailed analysis of variation in costs and cost-effectiveness. At the other end of the
spectrum, costs can be estimated by using reference costs derived from a non-patient-speciﬁc source, such as
diagnosis-related groups based on national administrative databases. This is referred to as the gross costing
or top-down method. Gross costing is usually faster and cheaper for the analyst than micro-costing, but may
be less accurate because relatively large resource units are measured. Micro-costing may be more reliable
and precise, but it can be expensive and not always practical (Mogyorosy and Smith, 2005). Moreover, because
of challenges in data collection, micro-costing studies do often not incorporate costs that are incurred jointly
with other diseases or interventions across the health facility or wider health system, which can lead to marked
underestimation of economic costs (Cunnama et al., 2016).
There were clear differences between country income groups regarding costing methods. The ingredients
approach was used as the sole method in 68% of studies set in LLMICs, compared with 30% and 10% of UMIC
and HIC studies, respectively. In contrast, reference costs (sometimes mixed with some micro-costing) were
used in 78% of HICs and 45% of UMICs, but not in any LLMIC studies. Secondary data, such as from other
peer-reviewed articles, were used in 28% of LLMICs, 23% of UMIC studies and 12% of HIC studies. Patient
invoices from user fees were applied as a proxy for costs in two studies, one set in Kenya (Shade et al., 2013)
and one set in Thailand (Muangman and Totanarungroj, 2012).
3.5. Cost data analysis
When patient-speciﬁc cost data are collected, as is usual when EE studies are undertaken alongside a
randomised clinical trial, researchers have the opportunity to conduct statistical analysis on patient-speciﬁc cost
Table III. Results of logistic regression to test for differences in methodological areas across country income groups
Methodological area Binary variable n
LLMIC
(%)
UMIC
(%)
HIC
(%)
Odds
ratio P-value
1 Availability of guidelines Guidelines available 195 1 18 50 6.66 <0.001
2 Research question Chronic disease studied 150 80 62 22 3.83 <0.001
3 Perspective Government perspective used 150 60 66 70 1.25 0.295
4 Cost data collection methods Ingredients approach 150 68 30 10 0.22 <0.001
5 Cost data analysis Patient-level cost data analysed 32 44 75 55 1.18 0.711
6 Outcome measure QALYs 150 28 42 66 2.24 <0.001
7 Modelling technique Markov model 150 16 38 50 2.21 <0.001
8 Cost-effectiveness threshold WHO (GDP or GNI-based) 150 52 46 6 0.32 <0.001
9 Uncertainty analysis Probabilistic sensitivity analysis 150 34 42 72 2.22 <0.001
10 Applicability At least one local author 150 82 82 98 2.17 0.021
LLMIC, low-income and lower-middle income countries; UMIC, upper-middle-income countries; HIC, high-income countries; QALYs,
quality adjusted life years; WHO, World Health Organization; GDP, gross domestic product; GNI, gross national income.
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data. This might include an analysis of uncertainty, adjusting for confounders and subgroup analysis. EE
guidelines in general do not, however, give detailed guidance on how patient level data should be analysed,
although the guidance of United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE)
makes clear that patient-level data is preferable to facilitate subgroup analysis (National Institute for Health
and Care Excellence, 2013).
The proportion of studies conducted alongside a clinical trial was highest in LLMICs, with 32% of studies.
Only 14% of studies from both UMICs and HICs were conducted alongside a clinical trial. The proportion of
these studies presenting statistical analysis of patient cost data was 44% in the LLMIC group, 75% in UMICs
and 55% in HICs. Hence, about half of papers across all income groups with patient cost available from clinical
trials did not present a detailed analysis of these data. Because of the small sample size, the odds ratio of 1.18
was not statistically signiﬁcant (Table III).
3.6. Outcome measures
The choice of outcome measure is important as it largely dictates the usefulness of the analysis. There is broad
agreement between health economists that it is preferable to use a composite outcome measure, which com-
bines length and quality of life into a single metric (Ramsey et al., 2005, NICE International, 2014). Disability
adjusted life years (DALYs) and quality adjusted life years (QALYs) are the most commonly used.
Composite measures facilitate comparisons among interventions against all health conditions, whereas
outcomes measured in natural units, such as ‘number of diabetes cases averted’, only permit comparisons with
ﬁndings from studies using the same, limited metric. However, measures in natural units can be useful for
budget allocations within a disease-speciﬁc programme. In clinical trials, effects are often measured by inter-
mediate or surrogate outcomes, such as ‘change in glycated haemoglobin’, to reduce the trial’s duration and
expense. Predicting long-term health effects in terms of length and quality of life from surrogate measures thus
presents a key challenge requiring decision analytic modelling (Ramsey et al., 2005).
Calculating QALYs or DALYs entails four main steps: (i) describing the health state; (ii) developing
preference scores or weights for the health state; (iii) determining the time spent in each health state; and
(iv) combining the information. Development of preference scores or weights for the health state is the most
methodologically challenging aspect and an area where DALYs and QALYs particularly differ (Gold et al.,
2002). Preference scores for QALYs are derived by asking patients to complete questionnaires about their
overall health status. These data are scored using a multi-attribute scoring function based on direct preference
measurement from random samples of the general population of the respective country. Two types of
preference-scored, multi-attribute health status classiﬁcation systems are in widespread use: the EuroQol
EQ-5D and the Health Utility Index (Torrance et al., 2002). Multi-attribute scoring functions for the EQ-5D
system are available for 20 HICs, four UMICs (Argentina, China, Hungary and Thailand) and two LLMICs
(Armenia and Zimbabwe) (EuroQol, 2015).
Disability adjusted life years were originally developed to facilitate comparisons of disease burden between
countries. The same disability weights are therefore used for all settings. In the original 1996 WHO Global
Burden of Disease study, 237 different disability weights were published (Murray, 1996). These were derived
by using the person trade-off approach with a group of experts (Fox-Rushby, 2002). The most recently updated
disability weights have been obtained from population surveys in ﬁve countries (Salomon et al., 2012).
In our cross-sectional analysis, QALYs were used in 66% of studies in HICs, 42% of UMICs and 28% of
LLMICs. DALYs were used in 2%, 18% and 30% of the HIC, UMIC and LLMIC papers, respectively. For
each level of increase in income group, the odds of using QALYs in the EE were 2.24 greater, and this relation-
ship was statistically signiﬁcant (Table III). Combining these ﬁgures, we ﬁnd that 68% of HIC, 60% of UMIC
and 58% of LLMIC studies used a composite outcome metric (i.e. DALYs or QALYs), indicating a very small
difference across income groups, which was not statistically signiﬁcant (odds ratio = 1.24, p=0.304). The
outcome measures in natural units included ‘diarrhoea case averted’ (Puett et al., 2013) and ‘detection of
individual with high cardiovascular risk’ (Selvarajah et al., 2013).
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3.7. Modelling techniques
Modelling is useful for extrapolating the time horizon to a lifetime and synthesising all available data (Sculpher
et al., 2006). A number of modelling techniques exist; the most appropriate depends on the research question.
For simple questions, a decision tree may be sufﬁcient. Markov models are especially helpful where there are
repeat events over time, such as in chronic conditions. For infectious diseases, transmission dynamic models
can account for herd immunity and other indirect effects (Drake et al., 2015). While EE guidelines are generally
not speciﬁc about which type of modelling approach should be used, the need for modelling is clear given
recommendations of a lifetime horizon, which is normally unavailable from observed data.
In our sample, there were marked differences among settings, both in the use of modelling per se and the
types of model used. Nearly half of LLMIC studies (48%) had no model or the type was not clear from the
description in the paper, whereas this was the case in 34% and 14% of papers from UMICs and HICs,
respectively. The most common approach in HICs was the Markov model (56% of the 43 models), which
may reﬂect that the majority of HIC papers assessed chronic conditions. None of the HIC studies used
transmission dynamic models, whereas 10% and 6% used such models in UMICs and LLMICs, respectively.
Microsimulation approaches were used in 12% of HIC, 6% of UMIC and 4% of LLMIC articles.
3.8. Cost-effectiveness thresholds
When the comparison of interventions in an EE does not reveal dominance (i.e. that one intervention is both
more effective and less costly than the other), decision makers must determine whether the additional costs
incurred by one intervention relative to another are worth its additional beneﬁts. In theory, all potential
interventions could be ranked from highest to lowest priority, taking into account cost-effectiveness and other
criteria, and designated for implementation in order of priority until the overall budget constraint is reached. In
practice, a variety of cost-effectiveness threshold values have been used to determine whether an intervention is
likely to be cost-effective, without directly comparing with every possible alternative use of the resources.
In our representative cross-section, 80% of HIC, 60% of LLMIC and 52% of UMIC studies referred to a
threshold. Of these, 87% and 88% of articles set in LLMICs and UMICs, respectively, referred to the WHO
thresholds, compared with only 8% in HICs. The WHO threshold deﬁnes ‘highly cost-effective’ interventions
as those costing less than per capita gross domestic product (GDP) and ‘cost-effective’ as those costing less
than three times per capita GDP (World Health Organization, 2015). The remaining four LLMIC studies used
arbitrary thresholds or compared against interventions that were already implemented. Two of the three UMIC
studies that used another threshold were set in Thailand and used Thailand’s national threshold of GNI per
QALY gained (Kulpeng et al., 2013, Rattanavipapong et al., 2013).
Of HIC studies employing a threshold, 28% (n=11) used the NICE thresholds of £20 000 or £30 000 per
QALY gained (National Institute for Health and Care Excellence, 2013). Of these, seven were from the UK,
two were multi-country studies from the UK and another European country, one was entirely set in Italy and
another in the USA. In HICs, 65% (n=26) used other thresholds. Seven of the 14 papers from the USA used
US$ 50 000 per QALY gained, and two identiﬁed thresholds based on speciﬁc health outcomes: £100 000 per
timely diagnosis of congenital heart disease (Ewer et al., 2012) and US$ 50 000 per alloimmunisation event
averted (Kacker et al., 2014).
As many as 96% of LLMIC, 82% of UMIC and 78% of HIC studies concluded that a new or additional in-
tervention would be highly cost-effective or cost-effective. It can be argued that thresholds set so high that
nearly all possible interventions are considered ‘cost-effective’ cannot contribute effectively to priority setting.
Shillcut and colleagues demonstrated that the seemingly arbitrary thresholds used in some HICs (including the
NICE threshold of £30 000 per QALY gained) were in fact consistent with approximately twice per capita GNI.
They also argued that GNI and GDP-based thresholds ‘may reinforce wide global inequities in health and
wealth’, ‘lead to total budgetary costs that are currently not sustainable’ and that ‘valuing health according
to income ignores the other dimensions of life that can be argued to have utility’ (Shillcutt et al., 2009). In line
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with this critique, Drake has argued for a minimum ‘transnational’ threshold, on the basis that ‘using country-
speciﬁc thresholds in cross-country analysis conﬂate cost-effectiveness with affordability’ (Drake, 2014).
The widespread use of the NICE thresholds in UK analyses is clearly driven by NICE’s explicit requirement,
which also makes clear that the NICE threshold is intended to reﬂect the ﬁxed budget constraint of the National
Health Service (NHS). However, recent empirical work using routine cost and health outcomes data from the
NHS estimated a threshold of £12 936 per QALY and indicated that even this far lower estimate was likely to
overestimate affordability (Claxton et al., 2015). The use of threshold values that are likely to be unaffordable
is thus common to all countries.
3.9. Uncertainty analysis
The impact on the result of parameter and structural uncertainties should be assessed in sensitivity analysis. The
simplest option is to vary one or more parameter estimates at a time and re-run the evaluation in a deterministic
sensitivity analysis. However, this does not allow for an overall assessment of the degree of uncertainty or most
probable estimates. Probabilistic sensitivity analysis (PSA) is undertaken by specifying parameters as distribu-
tions rather than point estimates and simultaneously varying all parameter estimates in a Monte Carlo simula-
tion. Thus, PSA does not only provide estimates of mean expected costs and effects but also accompanying
uncertainty ranges, typically expressed as cost-effectiveness acceptability curves or frontiers (Briggs, 2001).
In our cross-sectional analysis, there were differences across settings as to whether sensitivity analysis was
conducted at all and the type of analysis performed. Across LLMICs, UMICs and HICs, 22%, 16% and 4% of
papers, respectively, did not perform any sensitivity analysis. PSA was signiﬁcantly more common in HICs
where it was undertaken in 72% of all 50 studies, compared with 42% in UMICs and 34% in LLMICs
(Table III).
As all guidelines recommend exploration of uncertainty (Drummond et al., 2005), the complete lack of
sensitivity analysis in one-ﬁfth of LLMIC studies constitutes a weakness. The NICE methods guidelines
recommend PSA (National Institute for Health and Care Excellence, 2013), which may in part explain its high
usage in HICs; however, not all guidance contains this recommendation.
3.10. Applicability
Applicability refers to the extent to which results of EEs are relevant to local contexts and used by
policymakers in decision-making. In countries where EE is a requirement for pharmaceutical reimburse-
ments, they are clearly being used for decision-making. However, this criterion only captures decisions
at the highest level, and it does not show the extent to which conducted studies are aligned with public
health priorities.
The impact of EEs on healthcare decision makers is believed to be limited (Thurston et al., 2008). Hoffmann
and Graf von der Schulenburg surveyed decision makers from nine European countries and found reasons for
results of EEs not being widely used included institutional dimensions, such as difﬁculties in transferring
budgets, and lack of credibility of studies funded by pharmaceutical companies. A UK study found that while
decision makers believe that EEs are valuable in principle, their usefulness is limited because they do not
always apply to their settings (Hoffmann et al., 2002). Moreover, UK NHS decision makers have been found
to either not understand health economics outcome statements, such as incremental cost-effectiveness ratios
(ICERs) and QALYs, or consider these to be irrelevant (Duthie et al., 1999).
A systematic review on perceptions of health policymakers on their use of evidence found that the most
commonly mentioned facilitator of using research evidence in policymaking was ‘personal contact between re-
searchers and policymakers’, and similarly, the most commonly mentioned barrier was ‘absence of personal
contact between researchers and policymakers’ (Innvaer et al., 2002). A study on decision-making for vaccines
similarly found locally generated evidence to be critical (Burchett et al., 2012). Hence, policymakers are more
inclined to use study results if they or an institution they know is in direct contact with the researchers. As an
indicator of potential applicability, we explored whether studies were locally funded and whether authors were
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based in the study country. In our cross-sectional sample, 74% of HIC studies were locally funded, as were
60% of UMIC studies, but only 20% of LLMIC studies. We found that 98% of HIC studies included an author
afﬁliated with an institution located in at least one of the countries studied, compared with 82% in both UMICs
and LLMICs. This difference was statistically signiﬁcant (p=0.021) (Table III). As authorship is important
both for capacity development and for fostering relevant and applicable EEs, it is encouraging that a relatively
high proportion of LLMIC studies included at least one local author, despite the low proportion of domestic
funding. This ﬁnding does not, however, take into account author order or the nature of contributions from
different authors. Furthermore, the local authorship criteria is likely to be less relevant for LLMIC studies
funded and used by international donors, such as the Global Fund and the Bill and Melinda Gates Foundation
(Santatiwongchai et al., 2015).
4. DISCUSSION
We found that methods used for EEs particularly vary between income groups with regard to cost data collec-
tion, outcome measures, modelling techniques, cost-effectiveness thresholds and uncertainty analysis. There
were also signiﬁcant differences regarding availability of guidelines and research questions, but these two
aspects reﬂect contextual differences and not chosen research methods. While EEs also share many common
features across income groups, we have chosen to focus on differences, which have previously been noted
anecdotally but neither quantiﬁed nor addressed. By highlighting these differences, we aim to start a debate
about the underlying reasons for why they have occurred and to what extent the differences are conducive
for methodological advancements. Here, we discuss our perceptions of some of the underlying reasons for
methodological differences.
Firstly, genuine differences between settings, diseases, and health care systems rightly affect methodologi-
cal choices. While the speciﬁc health areas studied do not and would not be expected to correlate perfectly with
burden of disease, the greater focus on infectious diseases in EEs from LLMICs reﬂects real differences in
epidemiological proﬁles, which inﬂuence the appropriate type of modelling. Differences in the nature of
interventions evaluated may also to some extent appropriately reﬂect differing health system contexts; the
tendency of EEs in HICs to focus on relatively expensive new technologies and of LMICs to focus on complex
health systems interventions may reﬂect the greater supply and demand constraints on LLMIC health systems
(Vassall et al., 2016). Moreover, the large majority of new drugs are produced with HICs as the target market,
and it is important to assess their value-for-money (Trouiller et al., 2002).
The appropriate perspective may also be context speciﬁc. The difference between government and
societal perspectives will invariably be smaller when the bulk of health care costs are covered by the
government in settings with universal health care coverage compared with countries with limited social
security. Nonetheless, patients inevitably incur at least some costs during illness; productivity costs are
especially important for chronic conditions. Only 36%, 20% and 18% of studies from LLMICs, UMICs
and HICs in our cross-sectional sample took a societal viewpoint, respectively. Failure to capture ‘true’
efﬁciency by including costs from all payers is thus a shortcoming of studies from all income groups,
but the consequences are starkest in settings and for diseases where patients incur a relatively large
proportion of costs. A key reason for choosing a government perspective is most likely a desire for less
data collection; a societal perspective would often require patient interviews, which invariably increase
study expenses.
Secondly, there are different capacities within the health sector. For example, the lack of cost accounting
systems in LLMICs often necessitates an ingredients approach to costing or a combination of primary cost
data collection approaches (Cunnama et al., 2016). In HICs, there is much greater reliance on reference costs
rather than the ingredients cost approach. This is partly because these data are available and easily accessible,
but perhaps also because they are regarded as more nationally representative than costs collected in a
selection of health facilities. However, while reference costs are undoubtedly simpler to use, they may not
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fully capture changes in resource use; for example, an intervention may alter the quantity of staff time and
materials used in the course of a ‘patient bed-day’, and this change would not be reﬂected in a standardised
reference cost.
Thirdly, differing expectations and research environments may also shape method selection. Anticipa-
tions from funders, journals and peer reviewers as to the type of methods used and the sophistication of
the analysis are different between settings. For example, international donors funding studies in LLMICs
often prefer DALYs to QALYs as these better facilitate comparison between settings (Santatiwongchai
et al., 2015). In HICs with available multi-attribute scoring functions, ofﬁcial guidelines tend to require
QALYs. In LLMICs, the need to collect primary cost data, which involves substantial time and resources,
may reduce the scope within ﬁxed research budgets for extensive analysis and modelling, especially
where funders have not previously supported such work. Moreover, EEs from different regions are to a
large extent published in separate peer-reviewed journals with diverse methodological expectations (Pitt
et al., 2016). The journal Value in Health, for example, recently launched regional issues for Asia, Latin
America, Central and Eastern Europe, Western Asia and Africa, which seems to suggest that the main
issue of the journal is largely reserved for HICs. This separation discourages scholarly dialogue between
researchers working in different regions and risks permitting different standards to emerge across the
various issues.
Fourthly, differences in methods are also likely to stem from different health economics capacity. For
example, in UMICs and LLMICs, modelling and sensitivity analysis were less commonly used, which
may reﬂect a lack of technical expertise and shortage of trained health economists. Similarly, DALYs
are invariably easier to apply as they do not require locally validated tools. The fact that most EE
textbooks have been developed exclusively for audiences in high-income settings – omitting entirely,
for example, any guidance on the use of DALYs (Drummond et al., 2005, Drummond and Mcguire,
2001) until this year (Drummond et al., 2015) – has hindered research capacity development in lower-
income settings and collaboration between researchers across settings. Nonetheless, the growing number
of countries – particularly UMICs – producing EE guidelines is a positive sign and an opportunity to
strengthen EE research.
In conclusion, some of the methodological differences we have identiﬁed rightly reﬂect the contextual
heterogeneity across low-income, middle-income and high-income countries; however, other differences
appear less justiﬁed. In HICs, the widespread use of reference costs and frequent recommendation of
limiting the analysis to the government health sector perspective warrant greater scrutiny. In LLMICs,
particular efforts are needed for research in health-related quality of life measurements as well as
promotion of routine use of probabilistic sensitivity analysis, modelling where necessary, and statistical
analysis of cost data. Moreover, routine data systems for both cost and disease surveillance would greatly
facilitate LLMIC research. In all countries, further research is needed into cost-effectiveness thresholds.
Greater collaboration between researchers across settings could foster a stronger EE research community
and improve methods in all settings.
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